Navigation Links
Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Per Falk, M.D., Ph.D., as vice president for Clinical, Medical and Regulatory Affairs for North America. Dr. Falk joins the U.S. Executive Team and will report directly to Jerzy Gruhn, president of Novo Nordisk Inc., the Novo Nordisk U.S. affiliate, and senior vice president for Novo Nordisk A/S, North America.

Dr. Falk brings 23 years of medical, research and pharmaceutical experience to his new position where he will lead clinical research and medical affairs in endocrinology and biopharmaceuticals, as well as regulatory affairs and medical communications.

Dr. Falk joined Novo Nordisk in 2002 as a vice president to establish the Experimental Medicine unit in Denmark. Later he served the company in Tokyo where he was responsible for drug development and market authorization of Novo Nordisk's medical entities in Japan and Australia. In 2008, Dr. Falk transitioned to the United States as the associate vice president of Clinical Development & Medical Affairs - Diabetes & Metabolism where he was responsible for clinical development and medical affairs for all of Novo Nordisk's diabetes and metabolism products, including those in development and on the market.

"As a company, Novo Nordisk has exciting opportunities and ambitious targets in diabetes and biopharmaceuticals with the end goal of improving patients' lives," said Jerzy Gruhn, president of Novo Nordisk Inc. "Dr. Falk is a proven asset to the company and is the ideal leader to help drive the development and marketing of new and lifesaving products to benefit millions of patients across the continent."

Prior to joining Novo Nordisk, Dr. Falk held positions as Director for Gastrointestinal Pharmacology and Molecular Biology in AstraZeneca's CV/GI research unit in Molndal, Sweden. He also has served as a lecturer and associate professor at Karolinska Institute, as well as a post-doctoral fellow and instructor in molecular biology and pharmacology at the Washington University School of Medicine in St. Louis.

Dr. Falk earned his M.D. and Ph.D. from the University of Gothenberg in Sweden. He trained in laboratory medicine at Sahlgren University Hospital and internal medicine/gastroenterology at Karolinska University Hospital.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,550 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball
2. Novo Nordisk Insulin Analogs Have Proven Safety Profiles
3. Novo Nordisk Warns Customers About Stolen Insulin
4. Diabetes Experts Partner With Novo Nordisk to Provide New Patient Materials
5. Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S.
6. Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
7. Novo Nordisk Makes its Debut in FORTUNEs 100 Best Companies to Work For
8. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
9. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
10. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
11. Novo Nordisk Files Annual Report with the SEC
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: